Results

Total Results: 1,077 records

Showing results for "phase".

1021. AHRQ Slide Template 2009 (ppt file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/topic-refinement.ppt
      March 01, 2010 - growth hormone (rhGH), we needed to devise key questions that, when subsequently answered in the next phase … This completes the topic refinement project and sets the stage for the next phase, in which the key questions … Studies are evaluated in this phase to review methods and demographics, not results.

1022. Evidence Report on the (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
      November 01, 2010 - Abstracts from studies identified in the electronic literature searches, during the public comment phase … Similar to the abstract review process, reasons for exclusion of articles at the extraction phase will

1023. Untitled (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb_surveillance.pdf
      July 06, 2015 - angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase … Full text articles for all citations progressed through the title/abstract review phase were assessed … angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase … angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase … ;METHODS: PARAMOUNT was a phase 2, randomised, parallel-group, double-blind multicentre trial in patients

1024. Management of Infantile Epilepsies | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/management-infantile-epilepsy/research
      March 01, 2023 - Event Outcomes for Lamotrigine Findings Conclusion SOE   Non-serious events In the long-term open label phase … During the long-term open label phase, 8% had pneumonia (16/204), 6% (12/204) had status epilepticus, … During the long-term open label phase the rate was 9% (18/204) AEs rarely cause discontinuation low Levetiracetam

1025. Autism Spectrum Disorder — An Update | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/autism-update/research-protocol
      December 01, 2019 - Question 3 Are there any identifiable changes early in the treatment phase that predict treatment outcomes … Question 4 What is the evidence that effects measured at the end of the treatment phase predict long-term … investigative team will also scan the reference lists of articles that are included after the full-text review phase

1026. Breast-Abnormalities-Tests-Update Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-abnormalities-tests-update_executive.pdf
      February 01, 2012 - Detection and prediction of breast cancer using couble phase Tc-99m MIBI scintimammography in comparison … Comparison of double phase Tc-99m MIBI and Tc-99m tetrofosmin scintimammography for characterization … Diagnostic performances of double-phase tc-99m MIBI scintimammography in patients with indeterminate

1027. Methods Guide for Medical Test Reviews Chapter 2 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-topics_methods.pdf
      July 01, 2012 - Methods Guide for Medical Test Reviews Chapter 2 2-1 Chapter 2 Developing the Topic and Structuring Systematic Reviews of Medical Tests: Utility of PICOTS, Analytic Frameworks, Decision Trees, and Other Frameworks David Samson, M.S., Blue Cross and Blue Shield Association Karen M. Schoelles M.D., S.…

1028. Assessing-The-Risk-Of-Bias-In-Systematic-Reviews-Of-Health-Care-Interventions (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/assessing-the-risk-of-bias-in-systematic-reviews-of-health-care-interventions-01_0.pdf
      May 01, 2005 - the extent or comprehensiveness of reporting.a Reporting the Risk of Bias During the protocol phase

1029. Ced-Topic-Refinement (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/ced-topic-refinement.pdf
      November 01, 2022 - In response, the requirement was modified to reflect that existing evidence (such as from phase II

1030. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/antipsychotics-children-update-disposition-170621.pdf
      March 16, 2017 - not all effects are likely to become evident in all patients within the one-to-two month treatment phase … own “across study” subgroup analyses using study-level data on our variables of interest (e.g., phase … We are happy our interpretations were correct for the controlled phase. … Thank you for sharing the results from the open label phase, although this does not meet our inclusion

1031. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/antipsychotics-children-update-disposition-170621.pdf
      March 16, 2017 - not all effects are likely to become evident in all patients within the one-to-two month treatment phase … own “across study” subgroup analyses using study-level data on our variables of interest (e.g., phase … We are happy our interpretations were correct for the controlled phase. … Thank you for sharing the results from the open label phase, although this does not meet our inclusion

1032. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gerd-disposition-120104.pdf
      April 01, 2011 - Takeda has completed a phase 1, randomized, open-label, 2 period, crossover study to evaluate the effect … release (MR) - The objective of the study was to assess the safety of dexlansoprazole MR from the phase … Pediatric patients - Dexlansoprazole is not FDA approved for use in patients less than 18 years of age.1A phase … dexlansoprazole in adolescents 12-17 years of age with symptomatic GERD has been completed.8 A second phase

1033. Juvenile-Arthritis-Dmards Surveillance (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
      March 14, 2013 - psoriatic arthritis: results of a six- month, multicenter, randomized, double- blind, placebo-controlled, phase … A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of … AEs during double blind phase included 159 events w/ tocilizumab vs 38 w/ placebo including 60 infections

1034. Juvenile-Arthritis-Dmards Surveillance (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
      March 14, 2013 - psoriatic arthritis: results of a six- month, multicenter, randomized, double- blind, placebo-controlled, phase … A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of … AEs during double blind phase included 159 events w/ tocilizumab vs 38 w/ placebo including 60 infections

1035. McCormack-notes-151008 copy - Teresa (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/mccormack-presentation.pdf
      November 12, 2015 - McCormack-notes-151008 copy - Teresa My talk today is about engaging patients with  low health  literacy. 1 Health literacy is a key factor in securing access to healthcare services. So in my talk today, I’ll talk a little bit about health literacy and what it is, how we measure health literacy and the sta…

1036. Schwitzer_ECCS2012 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/schwitzer_eccs2012.pdf
      July 23, 2012 - Schwitzer_ECCS2012 Slide 1: Addressing  Tensions  When Popular Media and Evidence-­‐Based Care Collide Gary  Schwitzer Publisher,  HealthNewsReview.org Slide 2: Infoxication We are drowning people who are thirsty for just a sip of balanced infor…

1037. Disposition of Comments Report for Comparative Effectiveness Review No. 137 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/autism-update_disposition-comments.pdf
      August 06, 2014 - Behavioral Health and Wellness) General Are there any identifiable changes early in the treatment phase … Health and Wellness) General What is the evidence that effects measured at the end of the treatment phase

1038. Menopause-Protocol-130612 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/menopause-protocol-130612.pdf
      June 12, 2013 - In the title/abstract screening phase, all references will undergo dual review by a senior and a junior … will be pooled by using the methods of Curtin et al.,39, 40 or if not possible, using only the first phase … While complete specification of data to be extracted will be developed during the abstraction phase, … Phase III evaluation of fluoxetine for treatment of hot flashes.

1039. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/devdelays_adhd_autism_hi_impact.pdf
      January 01, 2012 - inclusion are those interventions expected to be within 0 to 4 years of potential diffusion (e.g., in phase … III trials for pharmaceuticals or biotechnologies or in phase II or a trial with some preliminary … Results The table below lists the six topics for which (1) preliminary phase III data were available … Currently interventions such as this humanoid robotic doll are in an early phase of development and

1040. PEPTIC ULCER #11 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1512.pdf
      December 01, 2015 - inclusion are those interventions expected to be within 0–3 years of potential diffusion (e.g., in phase … Results The table below lists two topics for which (1) preliminary phase III data for drugs or phase … fecal microbiota therapy for ulcerative colitis that are in clinical trials but have not yet reported phase